摘要
目的探究左西孟旦与多巴酚丁胺治疗失代偿性心力衰竭的临床效果。方法选取2017年1月至2018年1月我院收治的100例失代偿性心力衰竭患者为研究对象,将其按随机抽签分组方式分为甲组和乙组,每组50例。两组患者均接受常规综合治疗,甲组在此基础上应用左西孟坦,乙组使用多巴酚丁胺。比较两组患者的治疗效果。结果甲组的治疗总有效率显著高于乙组,差异有统计学意义(P<0.05);治疗后,两组患者的HR、PaCO2均显著降低,均显著升高,且甲组优于乙组,差异有统计学意义(P<0.05);甲组的不良反应总发生率明显低于乙组,差异有统计学意义(P<0.05)。结论左西孟旦治疗失代偿性心力衰竭患者的临床效果较好,可更好地控制患者病情,值得临床推广应用。
Objective To explore the clinical effect of levosimendan and dobutamine in the treatment of decompensated heart failure. Methods A total of 100 patients with decompensated heart failure admitted in our hospital from January 2017 to January 2018 were selected as the research objects. The patients were divided into group A and group B according to random lottery grouping, with 50 cases in each group. Both groups received routine comprehensive treatment, the group A was treated with levosimontan and the group B was treated with dobutamine on this basis. The therapeutic effects of the two groups were compared. Results The total effective rate of treatment in the group A was significantly higher than that of the group B, and the difference was statistically significant(P <0.05). After treatment, the HR and PaCO2 in both groups decreased significantly, PaO2 increased significantly, and those in the group A were better than the group B, and the differences were statistically significant(P<0.05). The total incidence of adverse reactions in the group A was significantly lower than that in the group B, and the difference was statistically significant(P<0.05). Conclusion Levosimendan has a good clinical effect in the treatment of decompensated heart failure, which can better control the patient’s condition. It is worthy of clinical popularization and application.
作者
杜曼
DU Man(Nanyang First People's Hospital,Nanyang 473000,China)
出处
《临床医学研究与实践》
2019年第27期35-36,共2页
Clinical Research and Practice